Nextcure Inc. (NXTC) NASDAQ

$3.63 -0.15 (-3.97%)

Market Cap: $100.72M

As of 05/18/22 04:00 PM EDT. Market closed.

(NXTC)

Nextcure Inc. (NXTC) NASDAQ

$3.63 -0.15 (-3.97%)

Market Cap: $100.72M

As of 05/18/22 04:00 PM EDT. Market closed.

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop ... read more

NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through its proprietary FIND-IO™ platform, NextCure studies various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Its initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO Compensation (Base)
$383,400
CEO Compensation (Total)
$2.50M
URL
Address
9000 Virginia Manor Rd Ste 200, Maryland, Beltsville, 20705-4214.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Full Time Employees
90
CEO Compensation (Base)
$383,400
CEO Compensation (Total)
$2.50M
Address
9000 Virginia Manor Rd Ste 200, Maryland, Beltsville, 20705-4214.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$0
Previous Close
$3.78
Days Range
$3.62 - $3.87
52 week range
$3.25 - $9.18
Volume
62,844
Avg. Volume (30 days)
140,310
Market Cap
$100.72M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
27,747,165
Open
$0
Previous Close
$3.78
Days Range
$3.62 - $3.87
52 week range
$3.25 - $9.18
Volume
62,844
Avg. Volume (30 days)
140,310
Market Cap
$100.72M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
27,747,165

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR NEXTCURE INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Heller Kevin N. Chief Medical Officer Jul 14, 2020 Option Exercise $1.77 27,229 48,195 49,011 Jul 16, 2020, 04:51 PM
Liu Linda SVP, Research Nov 27, 2019 Option Exercise $0.75 55,234 41,656 55,234 Feb 21, 2020, 04:11 PM
Sofinnova Venture Partners IX, L.P. 10% Owner Nov 15, 2019 Buy $36.75 150,000 5,512,500 2,671,856 Nov 19, 2019, 09:47 PM
Sofinnova Venture Partners IX, L.P. 10% Owner May 13, 2019 Buy $15.00 400,000 6,000,000 2,521,856 May 15, 2019, 05:59 PM
SHANNON TIMOTHY M Director May 13, 2019 Buy $15.00 50,000 750,000 2,254,442 May 13, 2019, 07:33 PM
Khuong Chau Quang Director May 13, 2019 Buy $15.00 350,000 5,250,000 2,711,013 May 13, 2019, 07:32 PM
Xu Stella Director May 13, 2019 Buy $15.00 125,000 1,875,000 1,103,570 May 13, 2019, 07:32 PM
CANAAN X L.P. 10% Owner May 13, 2019 Buy $15.00 50,000 750,000 2,254,442 May 13, 2019, 07:32 PM
ORBIMED ADVISORS LLC Director May 13, 2019 Buy $15.00 350,000 5,250,000 2,711,013 May 13, 2019, 07:32 PM
Buy Sale Option Exercise
Owner Relationship Date Value($)
Heller Kevin N. Chief Medical Officer 07/14/2020 48,195
Liu Linda SVP, Research 11/27/2019 41,656
Sofinnova Venture Partners IX, L.P. 10% Owner 11/15/2019 5,512,500
Sofinnova Venture Partners IX, L.P. 10% Owner 05/13/2019 6,000,000
SHANNON TIMOTHY M Director 05/13/2019 750,000
Khuong Chau Quang Director 05/13/2019 5,250,000
Xu Stella Director 05/13/2019 1,875,000
CANAAN X L.P. 10% Owner 05/13/2019 750,000
ORBIMED ADVISORS LLC Director 05/13/2019 5,250,000
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
03/31/2021
0.07%
3Q
12/31/2021
09/30/2020
0.33%
5Q
12/31/2021
03/31/2020
-5.90%
7Q

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2021
0.07%
3Q
09/30/2020
0.33%
5Q
03/31/2020
-5.90%
7Q